Prosecution Insights
Last updated: August 17, 2026

Examiner: WHITE, DAWANNA SHAR-DAY

Tech Center 1600 • Art Units: 1627

This examiner grants 62% of resolved cases

Performance Statistics

62.3%
Allow Rate
+2.3% vs TC avg
158
Total Applications
+20.3%
Interview Lift
1263
Avg Prosecution Days
Based on 114 resolved cases, 2023–2026

Rejection Statute Breakdown

4.0%
§101 Eligibility
13.6%
§102 Novelty
35.1%
§103 Obviousness
20.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18101772 COMPOUNDS AND METHODS FOR TREATING CANCER Non-Final OA Mayo Foundation for Medical Education and Research
17766189 IMMUNOMODULATORY IMIDE DRUGS AS ZETA-CHAIN-ASSOCIATED PROTEIN KINASE 70 (ZAP70) AGONISTS AND USES THEREOF Non-Final OA Dana-Farber Cancer Institute, Inc.
18755002 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER Non-Final OA VANDERBILT UNIVERSITY
18063604 COMPOSITIONS AND METHODS FOR IMPROVED MESENCHYMAL STEM CELL THERAPY Final Rejection The Chinese University of Hong Kong

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month